perspective of pharmaceutical molecular design

35
A perspective of pharmaceutical molecular design Peter W Kenny ([email protected])

Upload: peter-kenny

Post on 02-Jul-2015

268 views

Category:

Education


0 download

TRANSCRIPT

Page 1: Perspective of pharmaceutical molecular design

A perspective of pharmaceutical molecular design

Peter W Kenny ([email protected])

Page 2: Perspective of pharmaceutical molecular design

Some things that make drug discovery difficult

• Having to exploit targets that are weakly-linked to

human disease

• Inability to predict idiosyncratic toxicity

• Inability to measure free (unbound) physiological

concentrations of drug for remote targets (e.g.

intracellular or on far side of blood brain barrier)

Dans la merde : http://fbdd-lit.blogspot.com/2011/09/dans-la-merde.html

Page 3: Perspective of pharmaceutical molecular design

[𝐷𝑟𝑢𝑔 𝑿, 𝑡 ]𝑓𝑟𝑒𝑒

𝐾𝑑

Why is it drug discovery and not drug design?

Page 4: Perspective of pharmaceutical molecular design

In tissues

Free in

plasma

Bound to

plasma

protein

Dose of drug Eliminated drug

A simplified view of what happens to drugs

Page 5: Perspective of pharmaceutical molecular design

Pharmaceutical molecular design

• Control of behavior of compounds and materials by

manipulation of molecular properties

• Hypothesis-driven or prediction-driven

• Sampling of chemical space

– Does fragment-based screening allow better control of

sampling resolution?

Page 6: Perspective of pharmaceutical molecular design

Do1 Do2

Ac1

Kenny (2009) JCIM 49:1234-1244 DOI

Illustrating hypothesis-driven design

DNA Base Isosteres: Acceptor & Donor Definitions

Page 7: Perspective of pharmaceutical molecular design

Watson-Crick Donor & Acceptor Electrostatic Potentials for

Adenine IsosteresV

min

(Ac1)

Va (Do1)

Kenny (2009) JCIM 49:1234-1244 DOI

Page 8: Perspective of pharmaceutical molecular design

Choosing octanol was the first mistake...

Page 9: Perspective of pharmaceutical molecular design

Lipophilic & half ionised Hydrophilic & neutral

Introduction to partition coefficients

Page 10: Perspective of pharmaceutical molecular design

Polarity

NClogP ≤ 5 Acc ≤ 10; Don ≤5

An alternative view of the Rule of 5

Page 11: Perspective of pharmaceutical molecular design

Does octanol/water ‘see’ hydrogen bond donors?

--0.06 -0.23 -0.24

--1.01 -0.66

Sangster lab database of octanol/water partition coefficients: http://logkow.cisti.nrc.ca/logkow/index.jsp

--1.05

Page 12: Perspective of pharmaceutical molecular design

Octanol/Water Alkane/Water

Octanol/water is not the only partitioning system

Page 13: Perspective of pharmaceutical molecular design

logPoct = 2.1

logPalk = 1.9

DlogP = 0.2

logPoct = 1.5

logPalk = -0.8

DlogP = 2.3

logPoct = 2.5

logPalk = -1.8

DlogP = 4.3

Differences in octanol/water and alkane/water logP values

reflect hydrogen bonding between solute and octanol

Toulmin et al (2008) J Med Chem 51:3720-3730 DOI

Page 14: Perspective of pharmaceutical molecular design

-0.054

-0.086-0.091

-0.072

-0.104 -0.093

Hydrogen bonding of esters

Toulmin et al (2008) J Med Chem 51:3720-3730 DOI

Page 15: Perspective of pharmaceutical molecular design

DlogP

(corrected)

Vmin/(Hartree/electron)

DlogP

(corrected)

Vmin/(Hartree/electron)

N or ether OCarbonyl O

Prediction of contribution of acceptors to DlogP

DlogP = DlogP0 x exp(-kVmin)

Toulmin et al (2008) J Med Chem 51:3720-3730 DOI

Page 16: Perspective of pharmaceutical molecular design

Basis for ClogPalk model

log

Pa

lk

MSA/Å2

Kenny, Montanari & Propopczyk et al (2013) JCAMD 27:389-402 DOIKenny, Montanari & Propopczyk et al (2013) JCAMD 27:389-402 DOI

Page 17: Perspective of pharmaceutical molecular design

𝐶𝑙𝑜𝑔𝑃𝑎𝑙𝑘 = 𝑙𝑜𝑔𝑃0 + 𝑠 ×𝑀𝑆𝐴 −

𝑖

∆𝑙𝑜𝑔𝑃𝐹𝐺,𝑖 −

𝑗

∆𝑙𝑜𝑔𝑃𝐼𝑛𝑡,𝑗

ClogPalk from perturbation of saturated hydrocarbon

logPalk predicted

for saturated

hydrocarbonPerturbation by

functional groups

Perturbation by

interactions

between

functional groups

Kenny, Montanari & Propopczyk et al (2013) JCAMD 27:389-402 DOI

Page 18: Perspective of pharmaceutical molecular design

Performance of ClogPalk model

Hydrocortisone

Cortisone

(logPalk ClogPalk)/2

log

Pa

lk

Clo

gP

alk

AtropinePropanolol

Papavarlne

Kenny, Montanari & Propopczyk et al (2013) JCAMD 27:389-402 DOI

Page 19: Perspective of pharmaceutical molecular design

Another way to look at Structure activity relationships?

Page 20: Perspective of pharmaceutical molecular design

(Descriptor-based) QSAR/QSPR:

Some questions

• How valid is methodology (especially for validation)

when distribution of compounds in training/test space

is highly non-uniform?

• Are models predicting activity or locating neighbours?

• To what extent are ‘global’ models just ensembles of

local models?

• How well do the methods handle ‘activity cliffs’?

• How should we account for sizes of descriptor pools

when comparing model performance?

Page 21: Perspective of pharmaceutical molecular design

Measures of Diversity & Coverage

•• •

••

••

••

2-Dimensional representation of chemical space is used here to illustrate concepts of diversity

and coverage. Stars indicate compounds selected to sample this region of chemical space.

In this representation, similar compounds are close together

Page 22: Perspective of pharmaceutical molecular design

Neighborhoods and library design

Page 23: Perspective of pharmaceutical molecular design

Examples of relationships between structures

Tanimoto coefficient (foyfi) for structures is 0.90

Ester is methylated acid Amides are ‘reversed’

Page 24: Perspective of pharmaceutical molecular design

Leatherface molecular editor

From chain saw to Matched Molecular Pairs

c-[A;!R]

bnd 1 2

c-Br

cul 2

hyd 1 1

[nX2]1c([OH])cccc1

hyd 1 1

hyd 3 -1

bnd 2 3 2

Kenny & Sadowski Structure modification in chemical databases, Methods and Principles in Medicinal

Chemistry (Chemoinformatics in Drug Discovery 2005, 23, 271-285 DOI

Page 25: Perspective of pharmaceutical molecular design

Glycogen Phosphorylase inhibitors:

Series comparison

DpIC50

DlogFu

DlogS

0.38 (0.06)

-0.30 (0.06)

-0.29 (0.13)

DpIC50

DlogFu

DlogS

0.21 (0.06)

0.13 (0.04)

0.20 (0.09)

DpIC50

DlogFu

DlogS

0.29 (0.07)

-0.42 (0.08)

-0.62 (0.13)

Standard errors in mean values in parenthesis; see Birch et al (2009) BMCL 19:850-853 DOI

Page 26: Perspective of pharmaceutical molecular design

Effect of bioisosteric replacement

on plasma protein binding

?

Date of Analysis N DlogFu SE SD %increase

2003 7 -0.64 0.09 0.23 0

2008 12 -0.60 0.06 0.20 0

Mining PPB database for carboxylate/tetrazole pairs suggested that bioisosteric

replacement would lead to decrease in Fu so tetrazoles were not synthesised.

Birch et al (2009) BMCL 19:850-853 DOI

Page 27: Perspective of pharmaceutical molecular design

-0.316

-0.315

-0.296

-0.295

Bioisosterism: Carboxylate & tetrazole

-0.262

-0.261

-0.268

-0.268

Kenny (2009) JCIM 49:1234-1244 DOI

Page 28: Perspective of pharmaceutical molecular design

Amide N DlogS SE SD %Increase

Acyclic (aliphatic amine) 109 0.59 0.07 0.71 76

Cyclic 9 0.18 0.15 0.47 44

Benzanilides 9 1.49 0.25 0.76 100

Effect of amide N-methylation on aqueous solubility

is dependent on substructural context

Birch et al (2009) BMCL 19:850-853 DOI

Page 29: Perspective of pharmaceutical molecular design

Relationships between structures

Discover new

bioisosteres &

scaffolds

Prediction of activity &

properties

Recognise

extreme data

Direct

prediction

(e.g. look up

substituent

effects)

Indirect

prediction

(e.g. apply

correction to

existing model)

Bad

measurement

or interesting

effect?

Page 30: Perspective of pharmaceutical molecular design

• Molecular design is not just about prediction so

how can we make hypothesis-driven design more

systematic?

• There is life beyond octanol/water (and atom-

centered charges) if we choose to look for it

• Even molecules can have meaningful relationships

Some stuff to think about

Page 31: Perspective of pharmaceutical molecular design

Spares follow

Page 32: Perspective of pharmaceutical molecular design

The lurking menace of correlation inflation

Kenny & Montanari (2013) JCAMD 27:1-13 DOI

Page 33: Perspective of pharmaceutical molecular design

Preparation of synthetic data for correlation

inflation study

Add Gaussian

noise (SD=10) to Y

Kenny & Montanari (2013) JCAMD 27:1-13 DOI

Page 34: Perspective of pharmaceutical molecular design

Correlation inflation by hiding variationSee Hopkins, Mason & Overington (2006) Curr Opin Struct Biol 16:127-136 DOI

Leeson & Springthorpe (2007) NRDD 6:881-890 DOI

Data is naturally binned (X is an integer) and mean value of Y is calculated for

each value of X. In some studies, averaged data is only presented graphically

and it is left to the reader to judge the strength of the correlation.

R = 0.34 R = 0.30 R = 0.31

R = 0.67 R = 0.93 R = 0.996

Page 35: Perspective of pharmaceutical molecular design

r

N 1202

R 0.247 ( 95% CI: 0.193 | 0.299)

N 8

R 0.972 ( 95% CI: 0.846 | 0.995)

Correlation Inflation in FlatlandSee Lovering, Bikker & Humblet (2009) JMC 52:6752-6756 DOI

Kenny & Montanari (2013) JCAMD 27:1-13 DOI